Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that
redirect T cells to tumor surface antigens. While efficacious against certain hematological …

Talimogene laherparepvec (T-VEC) is a modified oncolytic herpes Simplex virus, type 1
(HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF). T-VEC is …

Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors
(ICI) in patients with melanoma have shown high clinical and pathologic response rates …

Since the US Food and Drug Administration first approved talimogene laherparepvec for the
treatment of melanoma in 2015, the field of oncolytic immunotherapy (OI) has rapidly …

Introduction Cutaneous melanoma is notorious for the development of in-transit metastases
(ITM). For unknown biological reasons, ITM remain the leading tumour manifestation without …

Combined oncolytic virotherapy and immunotherapy (immunovirotherapy) protocols
represent a promising treatment strategy for a range of cancers and offer many advantages …

The incidence of cutaneous melanoma is rapidly increasing worldwide. Cutaneous
melanoma is an aggressive type of skin cancer, which originates from malignant …

Abstract Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of
unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement …

Background In 2015, herpes simplex virus 1 (HSV-1)-derived talimogene laherparepvec (T-
VEC) was the first oncolytic virus approved by the US Food and Drug Administration as a …